The thinking: if the incretin pathway has reached maximum effect, stimulating a completely different pathway might restart progress without the gastrointestinal burden of higher tirzepatide doses
Product choice may depend on internal project planning, research governance, storage procedures and purchasing approval
It remains in Phase 3 clinical trials globally, with FDA approval projected for late 2026 or early 2027
Our ISO-certified laboratories employ advanced analytical methods including HPLC/LC-MS verification ensuring minimum 99.5% purity standards
AASLD guidance recommends considering them in patients with concurrent co-morbidities such as obesity and diabetes given their potential benefit in NAFLD
It also improved multiple cardiometabolic markers, including cholesterol, blood pressure, inflammation and waist size